A Comprehensive Genomic Profiling Study Comparing Primary Tumor, Metastatic Tumor Tissue, and Liquid Biopsy in Patients with Intrahepatic CCA

2020 Year in Review - Cholangiocarcinoma - Cholangiocarcinoma

Results of a comprehensive genomic profiling study indicate differences in genomic alterations detected from primary tumor, metastatic tumor tissue, and liquid biopsy in patients with intrahepatic CCA; IDH1 and FGFR2 genomic alterations are detectable in liquid biopsy, with potential practice-changing implications in clinical practice.

Genomic alterations that are characteristic of intrahepatic CCA are well known. Jeffrey S. Ross, MD, Medical Director, Foundation Medicine, Cambridge, MA, led a study that examined whether genomic alterations from a primary tumor would differ from metastatic tumor tissue and liquid biopsy in patients with intrahepatic CCA1; study results were presented at this year’s annual meeting of the American Society of Clinical Oncology (ASCO).

In patients with advanced-stage intrahepatic CCA, comprehensive genomic profiling was performed on 1268 tissue samples using primary tumor in 1048 cases, metastatic tumor in 220 cases, and 364 liquid biopsy cases (solid tissue, 318-327 genes; liquid biopsy, 72 genes).1

Tumor mutational burden was determined on the sequenced DNA. PD-L1 expression in tumor cells was measured by immunohistochemistry. The frequencies of untargetable genomic alterations were similar overall. Less frequent in metastatic tumors than in primary tumors were IDH1 and FGFR2 genomic alterations that are known to be enriched in intrahepatic CCA.

IDH1 and FGFR2 genomic alterations were identified with liquid biopsy. Genomic alterations uncovered in primary tumors versus metastatic tumors in advanced intrahepatic CCA were significantly different; the metastatic tumor cohort had primarily more KRAS and fewer IDH1 and FGFR2 genomic alterations.

These results suggest that the metastatic tumor group may contain patients without intrahepatic CCA whose metastatic lesions were derived from other primary sites and who were incorrectly diagnosed with intrahepatic CCA. Liquid biopsy detected more IDH1 genomic alterations than metastatic tumor biopsy, as well as other potentially targetable alterations.

Source: Ross JS, et al. J Clin Oncol. 2020;38(15_suppl). Abstract 4579.

Reference

  1. Ross JS, Sokol E, Pavlick D, et al. Primary tumor (p-bx) versus metastatic tumor (m-bx) tissue versus liquid biopsy (lb) in intrahepatic cholangiocarcinoma (IHCC): a comparative comprehensive genomic profiling (CGP) study. J Clin Oncol. 2020;38(15_suppl):Abstract 4579.
Related Items
Key Advances in the Treatment of Patients with BTC in 2023: New Targeted Therapies, Potential Biomarkers, and Combination Strategies
2023 Year in Review - Cholangiocarcinoma published on December 31, 2023 in Cholangiocarcinoma
KEYNOTE-966: Pembrolizumab Combined With GemCis Versus GemCis Alone in Patients With BTC
2023 Year in Review - Cholangiocarcinoma published on December 31, 2023 in Cholangiocarcinoma
Post-hoc Analysis of the ABC-01, -02, and -03 Trials in Patients With Advanced eCCA
2023 Year in Review - Cholangiocarcinoma published on December 31, 2023 in Cholangiocarcinoma
Efficacy and Safety of Tinengotinib in Patients With Advanced Refractory/Relapsed CCA Who Previously Received an FGFR Inhibitor
2023 Year in Review - Cholangiocarcinoma published on December 31, 2023 in Cholangiocarcinoma
KLF5 Inhibition Reduces Tumor Growth and Sensitizes to Chemotherapy-Induced Cell Death in Experimental Models of CCA
2023 Year in Review - Cholangiocarcinoma published on December 31, 2023 in Cholangiocarcinoma
Phase 2 Trial of SHR-1316 Plus IBI310 in Patients With Advanced iCCA After Inadequate Response to First-Line Therapy
2023 Year in Review - Cholangiocarcinoma published on December 31, 2023 in Cholangiocarcinoma
Examination of Patients With CCA Treated With Novel Targeted Therapies After Extended Molecular Profiling on Liquid Biopsies
2023 Year in Review - Cholangiocarcinoma published on December 31, 2023 in Cholangiocarcinoma
Phase 2 Component of the BEER-BTC Study: Comparing Bevacizumab Plus Erlotinib Maintenance Versus Observation in Patients With Advanced BTC
2023 Year in Review - Cholangiocarcinoma published on December 31, 2023 in Cholangiocarcinoma
The DEBATE Trial: Neoadjuvant Durvalumab Plus GemCis Versus GemCis Alone for Patients With Localized BTC
2023 Year in Review - Cholangiocarcinoma published on December 31, 2023 in Cholangiocarcinoma
The Phase 2 ADJUBIL Study of Durvalumab Plus Tremelimumab With or Without Capecitabine in BTC
2023 Year in Review - Cholangiocarcinoma published on December 31, 2023 in Cholangiocarcinoma
© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: